Valuation: Grifols, S.A.

Capitalization 5.86B 6.82B 5.37B 5.07B 9.37B 658B 9.52B 63.62B 24.9B 311B 25.58B 25.04B 1,083B P/E ratio 2026 *
12.7x
P/E ratio 2027 * 9.21x
Enterprise value 14.38B 16.72B 13.16B 12.43B 22.98B 1,615B 23.34B 156B 61.05B 762B 62.74B 61.41B 2,655B EV / Sales 2026 *
1.87x
EV / Sales 2027 * 1.69x
Free-Float
79.23%
Yield 2026 *
2.71%
Yield 2027 * 3.07%
1 day-0.75%
1 week+3.79%
Current month+6.29%
1 month+3.59%
3 months-13.42%
6 months-6.12%
Current year-10.99%
1 week 8.88
Extreme 8.882
9.6
1 month 8.62
Extreme 8.62
9.6
Current year 8.43
Extreme 8.432
11.7
1 year 8.43
Extreme 8.432
13.7
3 years 6.36
Extreme 6.362
15.92
5 years 6.36
Extreme 6.362
25.94
10 years 6.36
Extreme 6.362
34.31
Manager TitleAgeSince
Chief Executive Officer 57 31/03/2024
Director of Finance/CFO 49 15/09/2024
Compliance Officer 54 31/12/2013
Director TitleAgeSince
Chairman 76 24/01/2010
Director/Board Member 70 12/04/2000
Director/Board Member 62 23/05/2015
Change 5d. change 1-year change 3-years change Capi.($)
-0.73%+3.79%-0.02%-18.67% 6.82B
+3.09%-9.74%+5.69%-14.40% 66.11B
0.00%-0.71%+45.80%+173.31% 52.82B
-0.67%+33.70%+33.70%+33.70% 41.34B
+1.60%+2.87%-59.20%-67.44% 34.22B
-1.45%-8.18%+43.85%-39.12% 27.73B
+1.55%-1.76%+48.67%+52.71% 19.39B
+5.25%-4.56%+71.92%-61.88% 19.09B
+3.78%-4.96%+47.41%+112.10% 17.59B
+0.05%-0.95%+40.90%+82.91% 16.17B
Average +1.24%-3.31%+27.87%+25.32% 30.13B
Weighted average by Cap. +1.27%-4.77%+23.87%+30.63%

Financials

2026 *2027 *
Net sales 7.69B 8.94B 7.04B 6.65B 12.29B 864B 12.49B 83.45B 32.65B 408B 33.55B 32.85B 1,420B 8.21B 9.54B 7.51B 7.1B 13.12B 922B 13.33B 89.06B 34.85B 435B 35.81B 35.05B 1,516B
Net income 511M 594M 468M 442M 817M 57.4B 830M 5.55B 2.17B 27.1B 2.23B 2.18B 94.38B 704M 819M 645M 609M 1.13B 79.11B 1.14B 7.64B 2.99B 37.35B 3.07B 3.01B 130B
Net Debt 8.51B 9.9B 7.79B 7.36B 13.61B 956B 13.82B 92.39B 36.15B 451B 37.15B 36.37B 1,572B 8B 9.31B 7.33B 6.92B 12.79B 899B 12.99B 86.84B 33.98B 424B 34.92B 34.18B 1,478B
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (2.9%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).
Employees
25,000
Date Price Change Volume
21/05/26 9.474 -0.94% 296,195
20/05/26 9.564 +4.62% 2,477,577
19/05/26 9.142 -0.57% 1,281,290
18/05/26 9.194 +1.12% 2,257,088
15/05/26 9.092 -0.92% 1,857,325
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
9.564EUR
Average target price
14.65EUR
Spread / Average Target
+53.13%

Quarterly revenue - Rate of surprise